Yang Ning, Zhang Wenxi, He Tao, Xing Yiqiao
Eye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan, Hubei Province 430060, China.
J Ophthalmol. 2017;2017:5053035. doi: 10.1155/2017/5053035. Epub 2017 Mar 24.
Galectin-1 (Gal-1) has been proved to be an important factor in the process of tumor angiogenesis recently. As a small molecule, OTX008 serves as a selective inhibitor of Gal-1. In this study, the role of Gal-1 and the antiangiogenic effect of OTX008 on retinal neovascularization (RNV) were investigated using a mouse model of oxygen-induced retinopathy. The outcome indicated that Gal-1 was overexpressed and closely related to retinal neovessels in OIR. After intravitreal injection of OTX008 at P12, the RNV was significantly reduced at P17, measuring by cross-sectional H&E staining and whole-mount fluorescence. Our results demonstrate the inhibitory function of OTX008 on RNV, which provides a promising strategy of treating retinal angiogenic diseases such as retinopathy of prematurity and proliferative diabetic retinopathy.
近年来，半乳糖凝集素-1（Gal-1）已被证明是肿瘤血管生成过程中的一个重要因素。作为一种小分子，OTX008是Gal-1的选择性抑制剂。在本研究中，利用氧诱导视网膜病变小鼠模型研究了Gal-1的作用以及OTX008对视网膜新生血管形成（RNV）的抗血管生成作用。结果表明，Gal-1在氧诱导视网膜病变中过表达，且与视网膜新生血管密切相关。在出生后第12天玻璃体内注射OTX008后，通过横断面苏木精-伊红染色和整体荧光测量，出生后第17天视网膜新生血管明显减少。我们的结果证明了OTX008对视网膜新生血管形成的抑制作用，这为治疗诸如早产儿视网膜病变和增殖性糖尿病视网膜病变等视网膜血管生成性疾病提供了一种有前景的策略。
